Association of FMO3 variants and trimethylamine N-oxide concentration, disease progression, and mortality in CKD patients

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Robinson Cohen, Cassianne ^a   Newitt, Richard ^a   Shen, Danny D ^b   Rettie, Allan E ^b   Kestenbaum, Bryan R ^a   Himmelfarb, Jonathan ^a   Yeung, Catherine K ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLANILINE MONOOXYGENASE; TRIMETHYLAMINE OXIDE; BIOLOGICAL MARKER; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); METHYLAMINE; OXYGENASE; TRIMETHYLOXAMINE;

ADULT; ALLELE; AMINO ACID SEQUENCE; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FMO3 GENE; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; CHRONIC KIDNEY FAILURE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

BIOMARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; METHYLAMINES; MIDDLE AGED; OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE;

EID: 84983460359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161074     Document Type: Article

References (35)

1. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. The New England journal of medicine. 2005; 352(20):2049-60. Epub 2005/05/20. doi: 10.1056/NEJMoa043161 PMID: 15901858.
2. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Annals of internal medicine. 2005; 142(7):497-505. Epub 2005/04/06. PMID: 15809461.
3. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. The New England journal of medicine. 2004; 351(13):1285-95. Epub 2004/09/24. doi: 10.1056/NEJMoa041365 PMID: 15385655.
4. Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circulation research. 2015; 116(3):448-55. Epub 2015/01/20. doi: 10.1161/CIRCRESAHA.116.305360 PMID: 25599331; PubMed Central PMCID: PMC4312512.
5. Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. Journal of the American Society of Nephrology: JASN. 2015. Epub 2015/08/01. ASN.2014111063 [pii] doi: 10.1681/ASN. 2014111063 PMID: 26229137.
6. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472(7341):57-63. Epub 2011/04/09. doi: 10.1038/nature09922 PMID: 21475195; PubMed Central PMCID: PMC3086762.
7. Craig SA. Betaine in human nutrition. Am J Clin Nutr. 2004; 80(3):539-49. Epub 2004/08/24. 80/3/539 [pii]. PMID: 15321791.
8. Lang DH, Yeung CK, Peter RM, Ibarra C, Gasser R, Itagaki K, et al. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol. 1998; 56(8):1005-12. Epub 1998/10/17. S0006295298002184 [pii]. PMID: 9776311.
9. Bell JD, Lee JA, Lee HA, Sadler PJ, Wilkie DR, Woodham RH. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-Noxide. Biochim Biophys Acta. 1991; 1096(2):101-7. Epub 1991/02/22. PMID: 2001424.
10. Treacy E, Johnson D, Pitt JJ, Danks DM. Trimethylaminuria, fish odour syndrome: a new method of detection and response to treatment with metronidazole. J Inherit Metab Dis. 1995; 18(3):306-12. Epub 1995/01/01. PMID: 7474897.
11. Zhang AQ, Mitchell S, Smith R. Fish odour syndrome: verification of carrier detection test. J Inherit Metab Dis. 1995; 18(6):669-74. Epub 1995/01/01. PMID: 8750603.
12. Mackay RJ, McEntyre CJ, Henderson C, Lever M, George PM. Trimethylaminuria: causes and diagnosis of a socially distressing condition. Clin Biochem Rev. 2011; 32(1):33-43. Epub 2011/04/01. PMID: 21451776; PubMed Central PMCID: PMC3052392.
13. Koukouritaki SB, Poch MT, Henderson MC, Siddens LK, Krueger SK, VanDyke JE, et al. Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. J Pharmacol Exp Ther. 2007; 320(1):266-73. Epub 2006/10/20. jpet.106.112268 [pii] doi: 10.1124/jpet. 106.112268 PMID: 17050781.
14. Mao M, Matimba A, Scordo MG, Gunes A, Zengil H, Yasui-Furukori N, et al. Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis. Pharmacogenomics. 2009; 10(9):1447-55. Epub 2009/09/19. 10.2217/ pgs.09.77. PMID: 19761368. doi: 10.2217/pgs.09.77
15. Akerman BR, Lemass H, Chow LM, Lambert DM, Greenberg C, Bibeau C, et al. Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort. Mol Genet Metab. 1999; 68(1):24-31. Epub 1999/09/10. doi: 10.1006/mgme.1999.2885 S1096-7192(99)92885-8 [pii]. PMID: 10479479.
16. Treacy E, Johnson D, Pitt JJ, Danks DM. Trimethylaminuria, fish odour syndrome: a new method of detection and response to treatment with metronidazole. Journal of inherited metabolic disease. 1995; 18(3):306-12. Epub 1995/01/01. PMID: 7474897.
17. Zschocke J, Kohlmueller D, Quak E, Meissner T, Hoffmann GF, Mayatepek E. Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet. 1999; 354(9181):834-5. Epub 1999/09/15. PMID: 10485731.
18. Yeung CK, Adman ET, Rettie AE. Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria. Arch Biochem Biophys. 2007; 464(2):251-9. Epub 2007/05/29. doi: 10. 1016/j.abb.2007.04.014 PMID: 17531949; PubMed Central PMCID: PMC2039921.
19. Robinson-Cohen C, Littman AJ, Duncan GE, Roshanravan B, Ikizler TA, Himmelfarb J, et al. Assessment of Physical Activity in Chronic Kidney Disease. J Ren Nutr. 2012. S1051-2276(12)00118-5 [pii] doi: 10.1053/j.jrn.2012.04.008 PMID: 22739659.
20. Roshanravan B, Khatri M, Robinson-Cohen C, Levin G, Patel KV, de Boer IH, et al. A prospective study of frailty in nephrology-referred patients with CKD. Am J Kidney Dis. 2012; 60(6):912-21. doi: 10.1053/ j.ajkd.2012.05.017 PMID: 22770927; PubMed Central PMCID: PMCPMC3491110.
21. Robinson-Cohen C, Littman AJ, Duncan GE, Weiss NS, Sachs MC, Ruzinski J, et al. Physical Activity and Change in Estimated GFR among Persons with CKD. J Am Soc Nephrol. 2013. doi: 10.1681/ASN. 2013040392 PMID: 24335971.
22. Echeverria D, Woods JS, Heyer NJ, Martin MD, Rohlman DS, Farin FM, et al. The association between serotonin transporter gene promotor polymorphism (5-HTTLPR) and elemental mercury exposure on mood and behavior in humans. J Toxicol Environ Health A. 2010; 73(15):1003-20. Epub 2010/06/09. doi: 10.1080/15287390903566591 922753199 [pii]. PMID: 20526950; PubMed Central PMCID: PMC2882654.
23. Woods JS, Heyer NJ, Russo JE, Martin MD, Farin FM. Genetic polymorphisms affecting susceptibility to mercury neurotoxicity in children: summary findings from the Casa Pia Children's Amalgam clinical trial. Neurotoxicology. 2014; 44:288-302. Epub 2014/08/12. doi: 10.1016/j.neuro.2014.07.010 S0161-813X(14)00139-9 [pii]. PMID: 25109824; PubMed Central PMCID: PMC4176692.
24. Robinson-Cohen C, Littman AJ, Duncan GE, Weiss NS, Sachs MC, Ruzinski J, et al. Physical activity and change in estimated GFR among persons with CKD. Journal of the American Society of Nephrology: JASN. 2014; 25(2):399-406. Epub 2013/12/18. doi: 10.1681/ASN.2013040392 ASN.2013040392 [pii]. PMID: 24335971; PubMed Central PMCID: PMC3904564.
25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009; 150(9):604-12. Epub 2009/05/06. PMID: 19414839; PubMed Central PMCID: PMC2763564.
26. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1):121-30. Epub 1986/03/01. PMID: 3719049.
27. Bandyopadhyay A, Saxena K, Kasturia N, Dalal V, Bhatt N, Rajkumar A, et al. Chemical chaperones assist intracellular folding to buffer mutational variations. Nat Chem Biol. 2012; 8(3):238-45. Epub 2012/01/17. doi: 10.1038/nchembio.768 nchembio.768 [pii]. PMID: 22246401; PubMed Central PMCID: PMC3527004.
28. Shih DM, Wang Z, Lee R, Meng Y, Che N, Charugundla S, et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. Journal of lipid research. 2015; 56(1):22-37. Epub 2014/11/08. doi: 10.1194/jlr.M051680 jlr.M051680 [pii]. PMID: 25378658; PubMed Central PMCID: PMC4274068.
29. Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, et al. The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell Rep. 2015. Epub 2015/01/21. S2211-1247(14)01065-1 [pii] doi: 10.1016/j.celrep.2014.12.036 PMID: 25600868; PubMed Central PMCID: PMC4501903.
30. Bushueva O, Solodilova M, Churnosov M, Ivanov V, Polonikov A. The Flavin-Containing Monooxygenase 3 Gene and Essential Hypertension: The Joint Effect of Polymorphism E158K and Cigarette Smoking on Disease Susceptibility. Int J Hypertens. 2014; 2014:712169. Epub 2014/09/23. doi: 10.1155/ 2014/712169 PMID: 25243081; PubMed Central PMCID: PMC4163302.
31. Allerston CK, Shimizu M, Fujieda M, Shephard EA, Yamazaki H, Phillips IR. Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenet Genomics. 2007; 17(10):827-39. Epub 2007/09/22. doi: 10.1097/FPC.0b013e328256b198 01213011-200710000-00004 [pii]. PMID: 17885620.
32. Dolan C, Shields DC, Stanton A, O'Brien E, Lambert DM, O'Brien JK, et al. Polymorphisms of the Flavin containing monooxygenase 3 (FMO3) gene do not predispose to essential hypertension in Caucasians. BMC Med Genet. 2005; 6:41. Epub 2005/12/06. 1471-2350-6-41 [pii] doi: 10.1186/1471-2350-6-41 PMID: 16324215; PubMed Central PMCID: PMC1316875.
33. Treacy EP, Akerman BR, Chow LM, Youil R, Bibeau C, Lin J, et al. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet. 1998; 7(5):839-45. Epub 1998/05/23. ddb113 [pii]. PMID: 9536088.
34. Kaysen GA, Johansen KL, Chertow GM, Dalrymple LS, Kornak J, Grimes B, et al. Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis. J Ren Nutr. 2015; 25(4):351-6. Epub 2015/03/25. doi: 10.1053/j.jrn.2015.02. 006 S1051-2276(15)00065-5 [pii]. PMID: 25802017; PubMed Central PMCID: PMC4469547.
35. Poulsen LL, Hyslop RM, Ziegler DM. S-oxidation of thioureylenes catalyzed by a microsomal flavoprotein mixed-function oxidase. Biochem Pharmacol. 1974; 23(24):3431-40. Epub 1974/12/15. 0006-2952(74)90346-3 [pii]. PMID: 4441423.